關(guān)鍵詞

NK細(xì)胞 CD44+ 免疫檢查點(diǎn)阻斷 單細(xì)胞RNA測(cè)序 貝邁奇單抗 索樂匹尼布 替爾泊肽 肥胖 PKC抑制劑

?

#今日行業(yè)熱點(diǎn)#

①Cell：A pan-cancer single-cell panorama of human natural killer cells

人類自然殺傷(NK)細(xì)胞在腫瘤微環(huán)境中的表型和功能多樣性

DOI: 10.1016/j.cell.2023.07.034

②Cancer Cell：CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration

來自肺腺癌(ADC)中CD44+肺癌干細(xì)胞(CSCs)的血管周細(xì)胞通過g蛋白偶聯(lián)受體124 (GPR124)增強(qiáng)的跨內(nèi)皮遷移(TEM)導(dǎo)致腦轉(zhuǎn)移

DOI: 10.1016/j.ccell.2023.07.012

③Cancer Cell：Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

綜述：推進(jìn)癌癥免疫治療的新輔助免疫檢查點(diǎn)阻斷(ICB)策略

DOI: 10.1016/j.ccell.2023.07.011

④Cell Genomics：Polygenic regression uncovers trait-relevant cellular contexts through pathway activation transformation of single-cell RNA sequencing data

多基因回歸通過單細(xì)胞RNA測(cè)序(scRNA-seq)數(shù)據(jù)的通路激活轉(zhuǎn)化揭示與性狀相關(guān)的細(xì)胞背景

DOI: 10.1016/j.xgen.2023.100383

⑤iScience：A randomized clinical trial of Bermekimab treatment for clinical improvement of systemic sclerosis

臨床試驗(yàn)：全人源化IL-1α阻斷單克隆抗體貝邁奇單抗（Bermekimab）用于系統(tǒng)性硬化癥（SSc）的一項(xiàng)雙盲、隨機(jī)、安慰劑對(duì)照研究

DOI: 10.1016/j.isci.2023.107670

⑥iScience：Integrative analysis of single-cell RNA-seq and ATAC-seq reveals heterogeneity of induced pluripotent stem cell derived hepatic organoids

單細(xì)胞RNA測(cè)序（scRNA-seq）和單細(xì)胞染色質(zhì)開放性測(cè)序技術(shù)（scATAC-seq）的綜合分析揭示了誘導(dǎo)多能干細(xì)胞衍生的肝類器官的異質(zhì)性

DOI: 10.1016/j.isci.2023.107675

⑦選擇性小分子口服脾酪氨酸激酶（Syk）抑制劑索樂匹尼布(Sovleplenib)用于成人原發(fā)免疫性血小板減少癥（ITP）的中國(guó)關(guān)鍵性III期研究達(dá)到主要終點(diǎn)以及所有次要終點(diǎn)

⑧GLP-1R/GIPR雙靶點(diǎn)激動(dòng)劑替爾泊肽（Tirzepatide）減重適應(yīng)癥的上市申請(qǐng)獲得NMPA受理

⑨GLP-1/GCG雙重激動(dòng)劑BI456906（Survodutide）將啟動(dòng)用于超重或肥胖的三項(xiàng)注冊(cè)Ⅲ期臨床

⑩第一類蛋白激酶C（PKC）抑制劑?Darovasertib (IDE196)單藥用于原發(fā)性葡萄膜黑色素瘤（UM）患者的新輔助或輔助治療的Ⅱ期臨床首例患者給藥

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！